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Background: CF infants often do not grow as expected which adversely affects later clinical outcomes, thus sensitive early measures of growth
deﬁciency are important. This study compared attained growth for age with velocity standards to determine which better predicts growth deﬁcits at
24 months of age.
Methods: Growth deﬁciency in infancy based on weight and length velocity, and attained growth was calculated for 1992 infants in the US CF
Foundation National Registry using the World Health Organization (WHO) and US growth standards. One, two and three month increments were
used for calculating velocity and pooled for each age interval. Sensitivity and speciﬁcity of early indicators to predict growth deﬁciency at
24 months were calculated.
Results: Observed prevalence of weight deﬁciency (b10th percentile) during the ﬁrst year of life was 26.8% higher (95% CI = (25.6, 28.1%),
p b 0.001) on average when measured by attained weight for age than velocity. Attained weight for age at four months was a more sensitive
predictor of diminished weight for age (b10th percentile) at 24 months (sensitivity = 100%, 95% CI = (87, 100%)) than weight velocity
(sensitivity = 40%, 95% CI = (23, 59%)). Attained length at four months was more sensitive to detecting subsequent stunting (b10th percentile
length for age) (77%, 95% CI = (62, 87%)) than length velocity (30%, 95% CI = (19, 45%)).
Conclusions: In CF infancy, attained weight or length is more sensitive than velocity-based deﬁnitions for predicting subsequent diminished
growth.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Body weight; Length; Anthropometry; Reference standards1. Background
Cystic fibrosis (CF) is an autosomal recessive genetic disease
caused by a mutation in the CF transmembrane conductance⁎ Corresponding author at: Seattle Children's Research Institute, M/S: CW8-5b
PO Box 5371, Seattle, WA 98145, United States. Tel.: +1 206 884 1024; fax: +1
206 884 7504.
E-mail address: heltshe@u.washington.edu (S.L. Heltshe).
http://dx.doi.org/10.1016/j.jcf.2014.05.009
1569-1993/© 2014 European Cystic Fibrosis Society. Published by Elsevier B,.V. Aregulator (CFTR) gene [1]. Malabsorption and malnutrition are
among the earliest disease manifestations [2,3]. Inadequate weight
gain and growth during infancy and childhood are important
indicators of subsequent growth delay [4,5], cognitive develop-
ment [6] and morbidities in a myriad of disease settings [7–9].
Growth deficiencies in CF, as early as 2 years of age [10], have
been associated with both decreased lung function and survival
[11,12], with those falling below the 10th percentile in weight for
age having the poorest prognosis [13]. Recently published CF
Foundation (CFF) infant care guidelines [14] recommend the usell rights reserved.
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growth throughout infancy [15]; and while there are other
proponents of using incremental growth measures (i.e. rate of
change or velocity) as an alternative to attained growth for age
cut-points to monitor growth [15,16], there is no consensus
regarding criteria for defining growth failure [17], nor has
growth velocity ever been formally characterized in the CF
population.
Early monitoring of nutrition, weight and length is a
foundational component of clinical care for at-risk infants to
prevent growth deficiencies before they occur [18]. In this
study, we sought to compare traditional attained growth for age
with velocity metrics, and evaluated the ability of these different
measures in early infancy to predict growth at 24 months of age in
a cohort of infants born with CF. Two sets of standards are
available for assessing incremental growth in infancy: the US
Center for Disease Control recommended [19] World Health
Organization's (WHO) infant growth standards [20,21],
representing international current feeding and nutrient supple-
mentation practices, and the Guo et al. US (Guo-US) velocity
standards [15], recommended by the CFF infant care guidelines
[14]. In this paper we described and compared both sets of
standards for weight and length velocity in addition to attained
growth for age in infants with CF in an attempt to identify the
most sensitive, early indicators of growth failure at 24 months of
age. We hypothesized that velocity measures would be more
sensitive than attained weight and length for predicting subsequent
growth deficits.
2. Methods
2.1. Study population and variables
This retrospective cohort study utilized the US CFF Patient
Registry which contains longitudinal data on more than 27,000
patients at over 110 accredited CF care centers [22]. We included
newborns diagnosed with CF who were born between Jan 1,
2004 and Dec 31, 2008 and entered in the registry before
4 months of age. Follow-up data through Dec 31, 2009 were
included to allow for two year follow-up on most individuals.
The Institutional Review Board at Seattle Children's Hospital,
Seattle, Washington approved this study.
Encounter based weight and length measures were used for
calculating weight and length velocity as change in grams and
centimeters per unit time, respectively. The velocities were then
standardized to the WHO cohort [23] and the Guo-US standards
to generate age and sex specific percentiles. WHO provides
weight and length velocity charts for increments of 2, 3, 4, and
6 months duration (1 month increments are also given for weight
velocity only) at every age interval from zero to 24 months.
Guo-US provides weight standards at 1 month increments from 0
to 6 months of age, 2 month increments from 0 to 12 months of
age, and 3 month increments from 0 to 24 months; length
standards are published for 2 month increments from 0 to
6 months of age and 3 month increments from 0 to 24 months.
We utilized only the WHO 1, 2, and 3 month increments that
correspond with the Guo-US reference data. There are noguidelines for handling anthropometrics measured between
ages or at imprecise increment lengths. To limit bias and noise
while retaining enough data to perform the analysis, we restricted
all analyses to include only observations where a patient's weight
or length was recorded at an age no more than ±9 days (30% of a
month) from expected age at interval start (0–23 months), and
follow-up measures of weight or length recorded at 1 or 2 or
3 months ±6 days later (20% of a month). More details in
Supplemental Method section online. Attained weight and length
for age were scored to the WHO standard growth charts [20].
The 10th percentile of weight for age [12,13,18], and length
for age [13] were chosen as the primary measures of growth
failure at 24 months. The following thresholds were chosen as
potential early markers of deficits at 24 months in order to
compare velocity to attained growth for age and identify the
most sensitive predictor: 1) Guo-US 50th percentile for weight
velocity (CFF Infant Care Guidelines' recommendation [14])
and length velocity, 2) WHO standardized 2.5th, 5th, 10th, and
50th percentiles for weight and length velocity, 3) WHO
standardized 2.5th, 5th, and 10th percentiles for weight and
length for age. For the velocity measures, increment durations
(1, 2 or 3 months) were pooled by age interval and individuals
who fell below the threshold for any of the increments were
considered to have met the criteria. The 50th percentile threshold
was only applied to the velocity measures and was chosen as the
closest comparator to the CFF Infant Care Guidelines' recom-
mendation. The more conservative 2.5% threshold for defining
growth deficiency is recommended by WHO, acknowledging
that their standard cohort of infants is considered optimal as
opposed to typical [24]. The 5th and 10th percentile thresholds
for growth deficiency are commonly used clinically and reported
in the literature [17,25,26].
2.2. Statistics
Rates of growth deficiency by each definition were tabulated
cross-sectionally at each month and reported as a percentage.
McNemar's test for paired binary data was used to test for
differences between velocity and attained growth failure rates
averaged over the first year to avoid multiple testing, and Guo-US
versus WHO standards at each month. Sensitivity and specificity
estimates were used to examine the association between the early
metrics and weight and length for age at 24 ± 1 months of age
(defined as bWHO 10th percentile) in the subset of data with
eligible velocity measures. Wilson's 95% confidence intervals
(CI) were calculated for sensitivity and specificity measures.
Analyses were performed using SAS (version 9.2, SAS Institute
Inc., Cary, NC, 2009), and R (version 2.15, The R Foundation for
Statistical Computing, Vienna, Austria, 2012).
3. Results
The cohort was comprised of 1992 infants from whom over
11,000 length and weight measurements were derived from the
CFF Patient Registry from 2004 through 2009 meeting
eligibility criteria. This group had a median of 4 visits (interquartile
range = 3–6) where either weight or length velocity were
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tics of the cohort were: 50.6% male, 91.9% Caucasian, 9.6%
Hispanic, and 47.7% homozygous F508del. Newborn screen-
ing was responsible for 49.6% of diagnoses. Meconium ileus
was present in 26.5%, and 90.1% of the cohort was classified
pancreatic insufficient as defined by use of enzyme replace-
ment therapy. At least 9 months of follow-up was observed for
98.9% of the infants and 85.0% had 2 years of data in the
registry. Characteristics of the analysis set did not differ from
the overall sample of babies born during this time period
(Supplement Table 1), and weight and length measurements
meeting the specific velocity calculation criteria were similar
to those from the entire set (Supplement Fig. 2).3.1. Comparison of attained weight and length for Age to
velocity
In this analysis, we examined the percentage of infants with
CF who met traditional definitions of growth deficiency with
attained weight or length less than the 10th, 5th or 2.5th percentiles
for age. This was compared with corresponding percentages using
the WHO velocity standard percentiles. Fig. 1 and Table 1 show
that majority of anthropometric deficits occur at the youngest ages.
Attained weight for age identified more at risk infants (b10th
percentile) on average during the first year than the equivalentFig. 1. Percent of the CF infant cohort falling below attained growth for age (solid lin
standard percentiles (thickest, medium, and thinnest lines, respectively) for each of
increments for velocity measures (1, 2 and 3 months) are pooled by age interval.velocity based measure (26.8%; 95% CI = (25.6, 28.1%);
p b0.001). Similarly, lengths for age failure rates were on
average 27.3% (95% CI = (25.6, 29.1%); p b0.001) higher
during the first year than the corresponding 10th percentile
threshold forWHO length velocity. Supplemental material online
and Supplemental Fig. 3 provides a comparison of the US versus
WHO velocity standards in this population.3.2. Association between early growth deficiencies and subsequent
weight and length deficiencies
At 24 months of age 6.9% fall below the 10th percentile for
weight and 24.9% fall below the 10th percentile for length
(Table 1). Among those ‘at risk’ in weight, 81.8% were also
failing in length; whereas among those failing in length only
22.8% were also failing in weight. At 24 months 5.7% fall
below both weight and length thresholds. Table 2 shows the
sensitivity and specificity of growth failure information at early
ages (4, 6, 12, and 18 months) to predict weight for age below
the 10th percentile at 24 months of age. Attained weight and
length for age growth deficiencies at 4 months (using 2.5th, 5th
and 10th percentile thresholds) are sensitive predictors of weight
for age b10th percentile at 24 months (range = 76%–100%)
with specificity range of 56% to 83%. Sensitivity measures were
highest at 4 months of age. Fig. 2A shows that attained weight fores) and growth velocity (dashed lines) thresholds. The 10th, 5th, and 2.5th WHO
the attained and velocity growth charts at 2, 4, 6, 12, 18 and 24 months. All
Table 1
Percentage of cohort in nutritional failure by age for each anthropometric outcome, and thresholds for defining growth failure.
Age (months)
Outcome Threshold 2 (n = 425) 4 (n = 741) 6 (n = 671) 12 (n = 374) 18 (n = 403) 24 (n = 317)
Weight for age b10% 44.2 43.3 34.7 11 6.9 6.9
b5% 33.6 33.5 25.5 8.3 3.7 2.8
b2.5% 25.2 26.5 18.6 3.7 2.5 1.9
Weight velocity (Guo-US) b50% 61.4 50.6 42 48.1 56.1 59.3
Weight velocity (WHO) b50% 75.1 52.9 38.2 30.5 45.7 51.1
b10% 31.5 18.5 12.5 6.4 11.2 18.3
b5% 21.2 12 10.4 4.5 6.7 12.6
b2.5% 14.1 8.2 8.2 3.5 3.2 8.2
(n = 60) (n = 494) (n = 520) (n = 164) (n = 403) (n = 317)
Length for age b10% 30 37.9 32.7 26.8 23.3 24.9
b5% 27 26.9 26 17.7 15.9 17
b2.5% 20 20.2 17.9 10.4 12.2 11.4
Length velocity (Guo-US) b50% 40 56.5 41.9 45.7 53.1 57.4
Length velocity (WHO) b50% 72 54.3 38.3 38.4 53.3 58.7
b10% 43 23.3 17.5 20.7 25.8 30.3
b5% 38 18.8 14 13.4 19.9 24.3
b2.5% 33 16 9.6 13.4 16.9 19.9
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of diminished weight at 24 months (sensitivity = 100%, 95%
CI = (87, 100%)) than weight velocity (b10th percentile) at
4 months (sensitivity = 40%, 95% CI = (23, 59%)). A higher
weight velocity threshold at 4 months (bWHO 50th percentile)
improves the sensitivity (68%, 95% CI = (48, 82%)) and
specificity (42%, 95% CI = (37, 47%)), but it remains less
sensitive than weight for age (p = 0.04).
Attained lengths for age growth deficiencies (b10th percentile)
at 4, 6, 12 and 18 months are sensitive predictors of length for
age b10th percentile at 24 months (range = 73%–83%) with aTable 2
Sensitivity and specificity for measures and timepoints to predict weight for age at
Predictor Threshold Sensitivity
Age (months)
4 (n = 353) 6 (n = 343) 12 (n = 14
Weight for age b10% 100 91 64
b5% 96 82 45
b2.5% 92 76 36
Weight velocity (Guo-US) b50% 68 56 55
Weight velocity (WHO) b50% 68 56 45
b10% 40 26 18
b5% 32 21 18
b2.5% 24 15 18
(n = 223) (n = 229) (n = 72)
Length for age b10% 94 85 25
b5% 88 80 25
b2.5% 76 65 25
Length velocity (Guo-US) b50% 65 75 25
Length velocity (WHO) b50% 59 70 25
b10% 24 30 25
b5% 24 25 25
b2.5% 24 20 25specificity range of 72% to 91%. (Supplemental Table 2). Fig. 2B
indicates that attained length b10th percentile at 4 months was
more sensitive to detecting subsequent length failure (sensitivity =
77%, 95% CI = (62, 87%)) than length velocity (30%, 95% CI =
(19, 45%)). As with prediction of weight at 24 months, a higher
length velocity threshold at 4 months (50th percentile) improves
sensitivity (63%, 95% CI = (48, 76%)) to detect length failure at
24 months, but at the expense of sensitivity (49%, 95% CI = (49,
57%)). Falling below the 10th percentile in weight for age at
4 months was also a sensitive indicator of length faltering at
24 months (81%, 95% CI = (71, 88%)).24 months less than the World Health Organization (WHO) 10th percentile.
Specificity
Age (months)
6) 18 (n = 81) 4 (n = 353) 6 (n = 343) 12 (n = 146) 18 (n = 81)
33 56 63 83 94
33 68 73 93 95
33 78 81 95 95
100 46 55 40 33
100 42 60 67 50
0 81 84 90 91
0 88 88 91 94
0 92 90 93 95
(n = 66) (n = 223) (n = 229) (n = 72) (n = 66)
67 67 68 74 83
67 76 77 85 89
33 83 85 91 97
33 46 56 50 46
33 48 60 56 46
33 78 80 76 78
33 82 84 85 81
33 84 89 87 87
Fig. 2. Sensitivity and specificity of 4 month anthropometric measures to predict weight (3A) and length (3B) for age at 24 months (falling below WHO 10th percentile).
Weight/length for age bWHO 10th percentile at 4 months (square), weight/length velocity bWHO 10th percentile at 4 months (closed triangle), weight/length velocity bWHO
50th percentile at 4 months (open triangle). Lines are 95% CI.
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This retrospective analysis of growth data from nearly 2000
infants with CF failed to support this study's hypothesis and the
current CFF guideline's assertion [14], that velocity based
definitions of growth deficiencies are more sensitive to identifying
early growth failure and predicting subsequent growth than
traditional measures of growth attainment by age. Furthermore,
the results indicate that early growth faltering (at four months of
age) is most predictive of later growth deficiencies. While there
have been assessments of failure to thrive in CF childhood and
infancy [25–27] this is the first study we know of to evaluate the
two velocity standards (WHO and Guo-US) with respect to
attained growth and compare their sensitivity to detecting
subsequent growth deficiency in CF infants.
During the first year of life, inadequate attained weight and
length for age indicate greater deficits than thresholds based on
weight and length velocity. Because adverse health outcomes
are strongly associated with poor growth in infants with CF, themost sensitive measures should be used to prevent long-term
consequences. Why is there a discrepancy in these two measures?
We hypothesize that pancreatic enzyme replacement therapy and
nutritional supplements lead to increased (“catch-up”) velocity yet
it is inadequate to completely correct the deficit which is measured
by attained growth by age. In addition, the high correlation
between repeated weight and length for age percentiles in an
individual [28] compared to the variability of velocity measures
within an infant [21] could also account for the high sensitivity
when using attained weight and length to predict growth at
24 months.
The CFF Infant Care Guidelines recommend using the medians
for weight velocity tomonitor infant growth based onUS standards
[14]. We showed that the WHO velocity standards performed
similarly to the US standards in their ability to predict growth
deficits at 24 months, but neither was preferable to attained growth
measures at the earlier time points. The WHO velocity standards
were not available at the time the CFF Infant Care Guidelines were
written; however, comparing the CF infant population using both
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sub-optimal (b50th percentile) weight gain throughout infancy.
The differences in geographic and demographic composition [29]
or statistical methodologies [15,21] between the two standards may
account for these findings.
Weight and length at 24 months of age are a benchmark
because of their clinical implications in CF [10,18] and other
childhood diseases [7]. Weight for length or body mass index
were not considered in this population because stunting leads
the weight for length measures to look normal or above average
[12]. The WHO 10th percentile is a conservative criterion and
has been shown to be associated with subsequent pulmonary
function [12,13,18]; choosing a more strict definition (the 5th
or 2.5th percentile) would result in less stable estimates of
sensitivity because so few would be considered poor growers at
24 months. The 50th percentile was not evaluated as a 24 month
endpoint because this is considered the ideal state, not an indicator
of nutritional failure. The finding that 4 month anthropometric
measures are most predictive of 24 month weight and length
suggests that deficiency is pre-determined; however the question
remains whether this result is driven by genetic or environmental
factors [30]. The discordance at 24 months between those below
the 10th percentile in length and those ‘at risk’ in weight suggests
that there are modifiable as well as genetic factors at play. Given
the advent of newborn screening, prioritization of nutritional
interventions in the first few months of life may be a window
of opportunity and these findings suggest that careful study of
aggressive nutritional management early in life is warranted.
This study is based on an encounter based registry, where
sicker, smaller infants may be more likely to come to regular and
additional clinic visits, introducing a selection bias. However,
clinic attendance is particularly high during infancy in the
majority of CF care centers [22], and our strict age and increment
requirements may have alleviated this bias. Great care was taken
to ensure that age and length of the increments used to calculate
velocity were precise, and doing so limited the analysis to a small
subset of the cohort. Comparison of this subset to all of the
anthropometric data does not indicate a bias or lack of
generalizability. Neither the Guo-US nor theWHO documentation
provides guidance on interpolating scores for an infant. For
example, if a child is 3.5 months of age at baseline and 5.9 months
old at the next clinic or study visit, should the child be assessed
using the intervals that begin at three or four months of age?
Subsequently, should the two or the three month increment
standard be used? One month increments are known to be highly
variable [21], but otherwise optimal increment length to evaluate
rate of change is unknown. We employed only the incremental
WHO standards that matched the frequency of the Guo-US
standards for purpose of comparison; more research into the
behavior of velocity measures under specific conditions may better
inform clinicians and researchers in other disease settings.
Attained weight and length for age and velocity appear to
highlight different aspects of anthropometric deficiencies among
a large multi-center cohort of CF infants. Identification of growth
deficiency in infancy by attained weight and length is more
sensitive as a clinical predictor of future growth faltering
when compared to velocity based measures. Validation in anindependent cohort is needed to confirm these findings and a
prospective, observational study of CF infant growth and
nutrition currently in progress will afford additional evidence
to support or refute these results. Further research is under
way to examine whether the utility of velocity versus attained
growth are modified by CF complications or other factors
known to impact growth such as pancreatic status, meconium
ileus, and diagnosis through newborn screening. Our study
demonstrates the importance of focusing on attained growth,
particularly in the first few months of life, in infants with CF.
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